Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 2011 June 1; 121(6): 2326–2335.
Published online 2011 May 16. doi:  10.1172/JCI45794
PMCID: PMC3104759

Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease


Parkinson disease (PD) involves the selective loss of midbrain dopamine (mDA) neurons and is a possible target disease for stem cell–based therapy. Human induced pluripotent stem cells (hiPSCs) are a potentially unlimited source of patient-specific cells for transplantation. However, it is critical to evaluate the safety of hiPSCs generated by different reprogramming methods. Here, we compared multiple hiPSC lines derived by virus- and protein-based reprogramming to human ES cells (hESCs). Neuronal precursor cells (NPCs) and dopamine (DA) neurons delivered from lentivirus-based hiPSCs exhibited residual expression of exogenous reprogramming genes, but those cells derived from retrovirus- and protein-based hiPSCs did not. Furthermore, NPCs derived from virus-based hiPSCs exhibited early senescence and apoptotic cell death during passaging, which was preceded by abrupt induction of p53. In contrast, NPCs derived from hESCs and protein-based hiPSCs were highly expandable without senescence. DA neurons derived from protein-based hiPSCs exhibited gene expression, physiological, and electrophysiological properties similar to those of mDA neurons. Transplantation of these cells into rats with striatal lesions, a model of PD, significantly rescued motor deficits. These data support the clinical potential of protein-based hiPSCs for personalized cell therapy of PD.


Parkinson disease (PD) involves progressive loss of midbrain dopamine (mDA) neurons in the substantia nigra, leading to decreased levels of dopamine (DA) in the striatum, which causes dysfunctional movement symptoms such as bradykinesia, rigidity, and tremor (1). Available drugs offer only symptomatic relief and are associated with severe side effects such as dyskinesia. A promising alternative is cell-based transplantation therapy. Open-label transplantation trials using human fetal mesencephalic tissues have demonstrated that grafted cells can reinnervate the striatum, restore DA neurotransmission, and, in some patients, dramatically improve motor dysfunctions associated with PD, even after a decade (2). Unfortunately, fetal cell transplantation has significant ethical, technical, and practical limitations. The limited availability of fetal tissues and variable functional outcomes (3, 4) has created demand for a standardized and unlimited cell source for PD.

Since induced pluripotent stem cells (iPSCs) can be generated from patients’ tissues and differentiate into all lineage cell types, they are an ideal source of cells for personalized replacement therapy (59). To evaluate their potential for treating human disease, it is important to assess their differentiation and cellular properties. The majority of human iPSC (hiPSC) lines have been generated using lentiviral and retroviral methods, which are known to generate multiple chromosomal integrations and possible genetic dysfunction. To our knowledge, there have been no studies to date systematically comparing the physiological and differentiation properties of hiPSCs generated using different reprogramming methods.

To overcome the potential safety issues associated with using viruses, we recently generated the first hiPSC lines by direct delivery of 4 reprogramming proteins fused to a cell penetrating peptide (10). In the present study, we addressed whether hiPSCs generated using viral and protein reprogramming methods exhibit fundamental differences in their cellular, molecular, and differentiation properties and whether protein-based hiPSCs can efficiently generate functional mDA-like neurons.


Induction of hiPSCs into primitive neuroepithelial cell types.

To explore the potential of hiPSCs for cell therapy of PD, we evaluated 8 hiPSC lines (Table (Table1)1) generated by lentiviral transduction (Lenti-1–Lenti-4), retroviral transduction (Retro-1 and Retro-2), and direct delivery of arginine-tagged reprogramming proteins (Pro-1 and Pro-2). We also used human ES cell (hESC) lines H9 and HSF-6 as controls (Table (Table2).2). All 8 hiPSC lines exhibited morphological features typical of hESCs (e.g., large nucleus with prominent nucleoli; Supplemental Figure 1A; supplemental material available online with this article; doi: 10.1172/JCI45794DS1) and expressed undifferentiated hESC markers such as Oct4, Nanog, and tumor recognition antigens 1–60 and 1–81 (Tra-1-60 and Tra-1-81, respectively; Supplemental Figure 1B and data not shown). Since individual ES cell (ESC) and iPSC lines are known to have different propensities to differentiate into specific cell lineages (1113), we first optimized in vitro differentiation methods to generate neuronal precursor cells (NPCs) and DA neurons from these diverse hiPSC lines. Based on previous studies showing efficient neural induction and/or proliferation of NPCs on different feeder cells (1419), we first optimized the stromal coculture method to ensure efficient neural induction from hiPSC and hESC lines. As schematized in Figure Figure1A,1A, undifferentiated hiPSCs maintained on mouse embryonic fibroblasts (MEFs) were sequentially cocultured onto MS5 feeder cells and MS5 stably expressing sonic hedgehog (MS5-SHH). During this coculturing, hiPSCs and hESCs changed their morphology into compactly assembled and demarcated cells with abundant cytoplasm and then into tubular rosette-like structures abundantly expressing NPC-specific markers such as Pax6, nestin, and Sox2 (Figure (Figure1,1, B, C, and G–I). Expression of cadherin 2, type1 (Cdh2; also referred to as N-cadherin) was asymmetrically localized on the luminal side of the rosettes (Figure (Figure1,1, H and I), a characteristic feature of primitive neuroepithelial rosette structures (20, 21). Notably, supplementation of bFGF during the first week of coculture greatly enhanced yields of neural colony formation from certain hiPSC lines (especially Pro-1 and Pro-2; data not shown), probably by bFGF effects in increasing cell survival and neural specification of the differentiating hiPSCs (22). Using this optimized coculture method, all hiPSC and hESC lines generated primitive neural structures in greater than 50% of colonies within 3 weeks (Supplemental Figure 2A). These primitive neural colonies were harvested by mechanical dissection for the in vitro differentiation studies described below.

Figure 1
Sequential induction of hiPSCs toward NPCs and DA neurons.
Table 1
hiPSC lines used
Table 2
hESC lines used

Generation of midbrain-type NPCs and DA neurons from hiPSCs.

When neuroepithelial colonies were transferred to a fibronectin-coated (FN-coated) surface, the cells in the center of the colonies were proliferating and were positive for the NPC marker nestin and the proliferating cell marker Ki67, whereas the cells in the periphery underwent neuronal differentiation, emanating extensive neurites positive for the neuronal marker tubulin beta III (TuJ1) and the DA marker tyrosine hydroxylase (TH) (Figure (Figure1,1, D, J, and K). To obtain a more homogenous NPC population, the colonies were dissociated into single cells and cultured in the presence of bFGF, a mitogen for NPCs. At the same time, SHH and FGF8 were added to induce midbrain patterning of NPCs (Figure (Figure1A).1A). Based on this combination of (a) elimination of differentiated and differentiating neuronal cells by mechanical procedures, (b) selective proliferation of NPCs by addition of bFGF, and (c) induction of midbrain patterning by SHH and FGF8, a largely homogenous population of NPCs with midbrain marker expressions could be generated from all hiPSCs and hESCs tested. After 6 days of NPC induction of dissociated cells, 92.0% ± 0.4% (Lenti-3) and 86.4% ± 3.1 % (Pro-1) of the total cells were nestin+/Ki67+ NPCs (Figure (Figure1L).1L). Subpopulations of these NPCs expressed the embryonic midbrain-specific markers Pax2 and/or Pax5 (Figure (Figure1M).1M). mRNA expression of mDA-specific transcription factors (e.g., LMX1A, LMX1B, engrailed-1 [EN1], and NURR1) was upregulated during NPC induction and differentiation (Supplemental Figure 2B). Under terminal differentiation conditions after withdrawal of growth factors, hiPSC-derived NPCs (hiPSC-NPCs) predominantly differentiated into TuJ1+ neuronal cells (60%–70% of total cells), with a few GFAP+ astrocytes (<5%; Figure Figure1N1N and Supplemental Figure 3). CNPase+ oligodendrocytes were not detected (data not shown), probably because of their late developmental timing. Notably, a major proportion of TuJ1+ neuronal cells (35%–45%) was TH+ (Figure (Figure1O1O and Supplemental Figure 3). The next major neuronal subtype was serotonin+ neurons (5%–10%; Figure Figure1P1P and Supplemental Figure 3). We also observed minor populations of GABAergic or glutamatergic neuronal cells (Supplemental Figure 3 and data not shown).

Residual expression of exogenous reprogramming genes in differentiated cells.

An important concern regarding the clinical application of hiPSCs is the potential residual expression and/or reactivation of exogenous reprogramming genes, some of which are related to oncogenesis pathways (23). Residual reprogramming gene expression may also alter or block terminal differentiation of hiPSCs into certain cell lineages. To investigate these issues, we examined Oct4 expression in NPCs and neuronal cells derived from hiPSCs. Strikingly, Oct4 expression was clearly detected in NPCs derived from all 4 lentivirus-based hiPSCs (Figure (Figure2A),2A), although it was much weaker than that in undifferentiated hiPSCs, as examined by immunoreactivity (Supplemental Figure 4, A–C) and mRNA expression (Figure (Figure2D2D and Supplemental Figure 4D). In addition, Oct4 immunoreactivity was detected in subpopulations of TuJ1+ neuronal cells and TH+ DA neurons derived from lentivirus-based hiPSCs (Figure (Figure2B).2B). Furthermore, we found that Oct4 expression was significantly upregulated by cAMP treatment (Figure (Figure2C),2C), which indicates that certain signals in vitro or in vivo could reactivate these reprogramming genes. In contrast, Oct4 expression was not detected in NPCs or neuronal cells derived from retrovirus- or protein-based hiPSCs (Figure (Figure2A).2A). To address whether residual Oct4 expression in lentivirus-based hiPSCs originated from the endogenous or the exogenous virus-coded gene, we performed RT-PCR analysis using specific primers (Supplemental Table 2). This analysis revealed that during differentiation of lentivirus-based hiPSCs, exogenous OCT4 gene expression persisted (as did that of NANOG and SOX2), even after generating terminally differentiated neurons (Figure (Figure2D).2D). Interestingly, we found that endogenous OCT4 gene expression completely disappeared during neuronal differentiation of lentivirus-based hiPSCs, along with other ESC/iPSC markers DNMT3L, REX1, and GDF3, which indicates that an appropriate differentiation program is occurring even in the presence of residual exogenous reprogramming gene expression. This is consistent with our results showing that generation of NPCs, neuronal cells, and DA neurons from lentivirus-based hiPSCs was comparable to that of retrovirus- and protein-based hiPSCs (Figure (Figure1).1). To examine reprogramming gene expression more quantitatively, we performed real-time PCR analyses for OCT4 and NANOG genes (Supplemental Figure 5). Unlike endogenous gene expression being silenced during neuronal differentiation, expression levels of exogenous reprogramming factor genes in lentivirus-based hiPSCs were not silenced, but rather increased during neuronal differentiation (Supplemental Figure 5, C and F). Based on upregulation of exogenous gene expression by cAMP (Figure (Figure2C),2C), a possible explanation is that the presence of bFGF (which is known to activate the cAMP signaling pathway) and cAMP during NPC and DA neuronal differentiation, respectively, contributed to this increased exogenous reprogramming gene expression. However, it was noted that total levels of OCT4 and NANOG expression significantly diminished during neuronal differentiation (Supplemental Figure 5, A and D), which strongly suggests that the levels of exogenous gene expression represent a minor fraction of the total gene expression levels. It was previously reported that constitutive SOX2 overexpression inhibits neuronal differentiation (24), raising the interesting question of how efficient neuronal differentiation could occur despite residual SOX2 expression. Although more detailed analyses are warranted to address this question at the cellular and molecular levels, it is possible that remaining NPCs among differentiated cells contributed, at least in part, to the observed residual SOX2 expression. In support of this is the prominent expression of Sox2 in NPCs derived from either ESCs/iPSCs (Figure (Figure1I1I and ref. 25) or developing brains (26). As expected, expression of exogenous reprogramming genes was not detected at any stage of protein-based hiPSC differentiation.

Figure 2
Residual expression of reprogramming genes in differentiated cells from hiPSCs.

Expansion and senescence of hiPSC-NPCs.

We previously showed that mouse (27) and human (17, 28) ESC-derived NPCs are highly expandable and maintain differentiation potentials, in contrast to NPCs from embryonic brain. This proliferative capacity of NPCs is important for the development of cell therapy as well as other applications, such as disease mechanism studies and drug screening platforms. Like hESC-derived NPCs, NPCs from protein-based hiPSCs were stably expandable for at least 8 passages without any change in proliferation index, as examined by total cell number and population doubling level (PDL; Figure Figure3,3, A and B). PDLs of Pro-1–derived NPCs were 1.85 at passage 1 (P1) versus 1.50 at P8, and similar numbers of TuJ1+ and TH+ cells were generated from each passage (P2, 38.38% ± 2.54% TH+/TuJ1+; P8, 43.37% ± 3.52% TH+/TuJ1+; n = 3 coverslips per value; Figure Figure3C).3C). Strikingly, lentivirus-based hiPSC-NPCs abruptly stopped proliferating within 2–4 passages (Figure (Figure3,3, A and B). Furthermore, retrovirus-based hiPSC-NPCs similarly stopped proliferating within 3–4 passages, which indicates that this early senescence is not the result of residual expression of exogenous reprogramming genes, at least in retrovirus-based hiPSC-NPCs. Dramatic increases of apoptotic cell death were observed in passaged NPCs from both lentivirus- and retrovirus-based hiPSCs, but not in protein-based hiPSC-NPCs (Figure (Figure3D3D and data not shown). Since the prototype tumor suppressor P53 critically regulates replicative senescence and apoptosis (29, 30), we hypothesized that its expression/regulation may be altered, leading to early senescence in these virus-based hiPSC-NPCs. Indeed, upregulation/induction of P53 expression preceded cellular senescence of lentivirus- and retrovirus-based NPCs during passaging (Figure (Figure3E). 3E).

Figure 3
Protein-derived hiPSC-NPCs, but not lentivirus- or retrovirus-based NPCs, are highly expandable without losing their DA neurogenic potentials.

In vitro functional analyses of DA neurons derived from protein-based hiPSCs.

Experiments were carried out to determine whether protein-based hiPSCs can efficiently generate functional midbrain-like DA neurons in vitro. As shown in Figure Figure4,4, A–C, TuJ1+ cells differentiated from protein-based hiPSC-NPCs exhibited mature neuronal morphologies and expressed mature neuron marker genes (e.g., microtubule-associated protein 2 [MAP2], hNCAM, and HuC/D) at day 15 after differentiation in vitro. Electrophysiological properties of these neuronal cells were examined using standard whole-cell patch techniques. The cells showed high input resistance (2.37 ± 0.57 G ohm), similar to young neurons of hippocampi (31). Of the 48 cells examined, 39 were able to generate tetrodotoxin-sensitive action potentials in response to depolarizing current injection (Figure (Figure4D),4D), indicative of a Na+ spike, a hallmark feature of differentiated neurons. Importantly, the majority of TH+ cells (>90%) were mature DA neurons, as evidenced by coexpression of neuronal (e.g., hNCAM, HuC/D, and MAP2) and DA markers (vesicular monoamine transporter 2 [VMAT2] and DA transporter [DAT]; Figure Figure4,4, E–I). Furthermore, expression of mDA markers (e.g., Nurr1, EN1, the A9 marker potassium inwardly-rectifying channel, subfamily J, member 6 [GirK2]) and the A10 marker calbindin 1, 28 kDa, colocalized in subpopulations of TH+ neurons (Figure (Figure4,4, J–M). We also tested DA neurotransmitter release and DAT-mediated specific DA reuptake, critical processes in presynaptic mDA neurons. Although DA was minimally detected in Pro-1 NPC cultures before differentiation, it dramatically increased in the culture medium after 15 days of differentiation (Figure (Figure4O).4O). Furthermore, DA release was strikingly evoked by high potassium–induced depolarization stimulus in differentiated cells (basal, 0.49 ± 0.02 ng/30 min/well; evoked by 56 mM KCl, 5.23 ± 0.76 ng/30 min/well; n = 4; Figure Figure4,4, N and O). In addition, differentiated Pro-1 NPCs exhibited robust DA uptake activities (6.01 ± 0.14 fmol/min/well) compared with those from non–terminally differentiated cultures at the limit of detection (0.27 ± 0.08 fmol/min/well; n = 4; Figure Figure4P).4P). Taken together, our results show that mature midbrain-like functional DA neurons can be efficiently generated from protein-based hiPSCs.

Figure 4
Protein-based hiPSCs generate functional midbrain-like DA neurons in vitro.

Cell transplantation in PD rats.

To examine in vivo function of protein-based hiPSC–derived NPCs and/or DA neurons, transplantation studies were carried out in a well-established rodent model of PD. We used 3 different donor cell conditions for transplantation into the striatum of 6-hydroxydopamine–lesioned rats: condition 1, a high-concentration cell solution of Pro-1 NPCs (3 μl of 2.5 × 105 cells/μl); condition 2, a moderate-concentration cell solution of Pro-1 NPCs (3 μl of 1 × 105 cells/μl); and condition 3, the same moderate number of cells at day 5 of terminal differentiation (3 μl of 1 × 105 cells/μl). As examined by amphetamine-induced rotation scores, condition 1 resulted in a dramatic functional recovery in parkinsonian rats (Figure (Figure5A);5A); at 8 weeks after transplantation, the average rotation score decreased to 23.57% ± 5.48% (n = 9) of pretransplantation scores. Notably, 3 of the original 12 grafted animals died as a result of tumor growth before 8 weeks. Abundant TH+ cells (54,418 ± 23,660 cells/graft; Figure Figure5L)5L) were observed in the grafted brains of surviving rats 8 weeks after transplantation (Figure (Figure5H).5H). However, these grafts were large (occupying more than half the striatum, 24.57 ± 9.75 mm3; Figure Figure5,5, B and K) and contained numerous neuroepithelial rosette structures (Figure (Figure5E)5E) with cells positive for nestin and the proliferating cell markers (Supplemental Figure 6), indicative of robust cell proliferation and remaining immature cells. Under condition 2, a moderate but significant level of functional recovery was observed (e.g., 52.46% ± 6.28% of pretransplant rotation scores at 8 weeks after transplantation; n = 6; Figure Figure5A),5A), without any graft-related death. The graft size was more appropriate and uniform (4.74 ± 1.94 mm3; Figure Figure5,5, C and K), without irregular proliferating mass or rosette formation (Figure (Figure5F).5F). TH+ cells (26,882 ± 9,089 cells/graft) were evenly distributed throughout the grafts (Figure (Figure5,5, L and I). A majority of TH+ cells coexpressed TuJ1 and VMAT2; moreover, some were positive for Nurr1 and EN1 (Figure (Figure5,5, N–R). This is in sharp contrast to condition 1, in which the graft size was substantially larger, tumor-related death occasionally occurred, and a huge number of proliferating/undifferentiated cell mass was found. In addition, TH+ cells were not detected in proliferating NPC masses, but were mostly found at the interphase between proliferating/undifferentiated cell clusters, indicative of inefficient NPC differentiation in condition 1. These findings emphasize the importance of optimizing the number and condition of transplanted cells to assure optimal outcomes. Notably, under condition 3, no behavioral recovery was observed, and no TH+ cells were readily detectable in the graft (Figure (Figure5,5, A, J, L, and M). Severe cell death was evident from the central area of the grafts (Figure (Figure5,5, D and G), which strongly suggested that the differentiation stage is a critical factor for functional outcomes of cell transplantation.

Figure 5
In vivo analyses of protein-based hiPSC-NPCs transplanted to PD model rats.


Although hiPSCs hold great promise as platforms to study and treat human disorders, it is critical to carefully assess their safety for clinical and biomedical application. In particular, hiPSCs generated using retroviruses and lentiviruses have chromosomal integrations that may lead to unpredictable genetic dysfunction. Our present results demonstrated that there was residual exogenous gene expression even when lentivirus-based hiPSCs were terminally differentiated into NPCs or neurons. In contrast, expression of the reprogramming genes was not readily detected in retrovirus-based hiPSCs after neural differentiation, indicative of almost complete silencing of exogenous genes. At present, it is not known why exogenous reprogramming genes exhibit differential silencing in lentivirus- and retrovirus-based hiPSC lines. Interestingly, during hematopoietic differentiation of mouse ESCs, gene expression from the retrovirus long terminal repeat (LTR), but not from the lentivirus, was severely reduced (32), which appears to be caused by methylation of the retroviral LTR promoter (33). Thus, it is possible that differential promoter methylation underlies the distinct silencing between lentivirus- and retrovirus-based hiPSCs.

Although NPCs derived from retrovirus- and lentivirus-based hiPSCs displayed limited expandability and early senescence, neuronal differentiation appeared to occur normally in all hiPSCs, as evidenced by efficient generation of NPCs and DA neurons under our optimized procedure. These observations suggest that retrovirus- and lentivirus-based hiPSCs may be useful for a variety of biological and neurorepair studies, even if they are an unsuitable source of cells for future personalized medicine. A recent study demonstrated that hiPSCs generated by the lentiviral method exhibit neural differentiation capacity with significantly reduced efficiency and increased variability compared with hESCs (13). We also recently showed that derivative cells (e.g., hemangioblasts, endothelial cells, and hematopoietic cells) could be generated from lentivirus- and retrovirus-derived hiPSC lines with phenotypes similar to those derived from hESCs, but with a dramatic decrease in efficiency (34). In distinct contrast to the hESC derivatives, hemangioblasts derived from virus-based hiPSCs showed significantly increased apoptosis, severely limited expansion capability, and substantially decreased hematopoietic colony-forming capability. Taken together, these results suggest that limited expandability and early senescence of derivative precursor cells is a common phenomenon for lentivirus- and retrovirus-based hiPSCs with genomic disruptions. Interestingly, we found that P53 expression was induced in apoptotic NPCs derived from lentivirus- and retrovirus-based hiPSCs before they underwent massive apoptosis. Why P53 is induced in these cells, but not in NPCs derived from hESCs or protein-based hiPSCs, warrants further investigation.

To overcome the potential caveats associated with residual exogenous reprogramming genes and chromosomal integrations, several groups have recently reported new approaches of hiPSC generation, including use of minimal numbers of reprogramming genes (35), use of small molecules (36, 37), excision of the remaining transgenes (3840), and use of nonintegrating vectors (41, 42). It will be important to determine whether these hiPSCs behave similarly to hESCs and protein-based hiPSCs in terms of differentiation and function of their derivative progenitor cells.

To our knowledge, this is the first study to directly compare the differentiation and cellular properties of hiPSCs generated by chromosome integrating and nonintegrating methods. A potential limitation of this work is that we used disparate hiPSC lines derived from different cell sources, at different passages, and handled by different laboratories, any of which can substantially affect the properties of individual hiPSC lines. Thus, a more straightforward comparison could be made using individual hiPSC lines generated from the same cell source via different reprogramming methods and used at similar passage and culture conditions. Despite these possible limitations, our data demonstrate fundamental and consistent differences in cellular and differentiation properties within each group of hiPSC lines without any exception, which strongly supports that these results are not due to experimental artifacts. Thus, our results suggest that protein-based hiPSCs may serve as a promising source of cells for clinical translation. These cells behaved similar to hESCs without abnormal senescence/apoptosis, they did not show any exogenous reprogramming gene expression, and DA neurons derived from protein-based hiPSCs significantly improved behavioral defects in a rodent model of PD. A high number of TH+ neurons (>25,000 cells/graft) survived over months after transplantation with prominent behavioral effect. This is in clear contrast to most hESC/hiPSC transplantation studies, which show only modest behavioral improvements in rodent PD models with much fewer surviving TH+ neurons (e.g., refs. 43, 44). Although it is not clear whether these differences are related to the hiPSC lines used in the present studies and how they were derived, it is likely that our optimized differentiation protocol and/or the stage of cell transplantation contributed to the different functional outcomes. In line with this, no functional recovery was observed when we transplanted the differentiated cells. Although tumorigenic masses were observed when a large number of cells was transplanted, this was most likely caused by the remaining undifferentiated cells. This underscores the importance of establishing clinically safe methods for complete removal of undifferentiated cells, as evidenced by a recent comprehensive study of multiple mouse iPSC lines showing the correlation of teratoma-forming propensities and remaining undifferentiated cells (12). Our results suggest that protein-based reprogramming may be a viable approach for generating a patient-specific source of cells for treatment of PD and other degenerative diseases.


Study approval.

Studies using hESCs and hiPSCs were approved by the IRB at Hanyang University and by the Partners Human Embryonic Stem Cell Research Oversight (ESCRO) Committee (protocol no. 2006-06-01). The IACUC of Hanyang University College of Medicine approved all protocols for animal care and treatment in this study.

Differentiation of hiPSCs and hESCs.

The hiPSCs and hESCs used in this study are listed in Tables Tables11 and and2.2. Undifferentiated hiPSCs and hESCs were propagated on MEF feeder and differentiated toward midbrain-type NPCs on feeder layers of MS5 and subsequently on MS5-SHH as previously described (17, 45). bFGF (20 ng/ml) was supplemented during the first week of the coculture period. Neuroepithelial cell colonies were transferred onto polyornithine/FN-coated dishes and cultured for the proliferation and midbrain patterning of NPCs for 7 days in ITS media plus AA (ITSA; 200 μmol/l) supplemented with bFGF (20 ng/ml), SHH (200 μg/ml), and FGF8 (100 μg/ml; R&D Systems). The expanded cell clusters were dissociated into single cells after incubating in Ca+2/Mg+2-free Hanks balanced salt solution for 30 minutes, and subcultured in the same expansion medium (NPC P1). The NPCs were subcultured every 7 days. Terminal differentiation of hiPSC- and hESC-derived NPCs was induced in ITSA supplemented with dibutyryl cAMP (0.5 mmol/ml; Sigma-Aldrich), brain-derived neurotrophic factor (BDNF; 20 ng/ml), and glial cell line–derived neurotrophic factor (GDNF; 20 ng/ml; R&D Systems). The NPCs at every passage were stored in liquid N2 and recultured when required.

Immunofluorescent staining.

Cultured cells or cryosectioned brain slices were fixed with 4% paraformaldehyde in PBS and incubated overnight at 4°C with primary antibodies listed in Supplemental Table 1. Appropriate fluorescence-tagged secondary antibodies (Jackson Immunoresearch Laboratories) were used for visualization. Stained samples were mounted in VECTASHIELD with DAPI mounting medium (Vector Laboratories) and photographed using epifluorescence and confocal microscope (Leica). Measurement of fluorescence intensity was computed with the Leica Application Suite (LAS) image analysis package.

Semiquantitative and quantitative RT-PCR.

Total RNA preparation, cDNA synthesis, and RT-PCR reactions were performed as described previously (45). Real-time PCR was performed on a CFX96 Real time system using iQ SYBR green supermix (Bio-Rad). Gene expression values were normalized to those of GAPDH. See Supplemental Table 2 for primers.

Measurement of cell expansion.

NPCs derived from each hiPSC and hESC line were expanded for 56 days by passaging every 7 days (total 8 passages). Cell expansion of each NPC passage was estimated by PDL, calculated as logN/No/log2, where N is the number of cells at the end of each passage and No is the number of cells plated initially (2.5 × 105 cells/cm2). Cumulative (total) PDL is the sum of individual PDLs up to NPC P8. For NPC cultures in which cell growth stopped earlier than P8 (Lenti-1–Lenti-4, Retro-1, and Retro-2), the cumulative PDL values are the sum of PDLs during sustained cell growth (PDL > 0).

Apoptotic cell detection by annexin V and propidium iodide.

Apoptotic cells were labeled with annexin V–FITC and propidium iodide using the annexin V–FLUOS staining kit (Roche) according to the manufacturer’s instructions.

Western blot analyses.

Cell lysis and immunoblotting were done as previously described (46). Proteins were extracted in lysis buffer, subjected to denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis, and transferred to a nitrocellulose membrane. Transferred proteins were blocked in 5% nonfat milk in 0.001% Tween 20 with Tris-buffered saline. The blot was probed with anti-mouse P53 (1:1,000 dilution; Cell Signaling) followed by treatment with anti-mouse IgG antibodies conjugated with peroxidase (1:2,000 dilution; Cell Signaling). Bands were visualized by enhanced chemiluminescence (Welgene).


Whole-cell patch recordings were made at 30°C with an EPC10/2 amplifier (HEKA). The bathing solution contained 124 mM NaCl, 26 mM NaHCO3, 3.2 mM KCl, 2.5 mM CaCl2, 1.3 mM MgCl2, 1.25 mM NaHPO4, and 10 mM glucose and saturated with 95% O2 and 5% CO2. The pipette (3–4 MΩ) solution for whole-cell patch clamp contained 140 mM K-gluconate, 5 mM di-Tris-phosphocreatin, 5 mM NaCl, 4 mM MgATP, 0.4 mM Na2GTP, 15 mM HEPES, and 2.5 mM Na pyruvate at pH 7.3 (adjusted with KOH).

DA uptake assay.

DA uptake in intact cells was conducted as described previously (45). Briefly, experiments were carried out at 37°C for 10 minutes using 50 nmol/l [3H]DA (51 Ci/mmol; Amersham Co.) with or without 10 μmol/l nomifensine (RBI), a DAT blocker, to determine nonspecific uptake. After incubation, uptake reactions were terminated by aspiration of the reaction solution and washing twice with ice-cold PBS. Cells were lysed with 0.5 mol/l NaOH, and the radioactivity was measured by liquid scintillation counting (Perkin Elmer). Specific DA uptake was calculated by subtracting nonspecific uptake (with 10 μM nomifensine) from the uptake value without nomifensine.

DA release by HPLC.

HPLC analysis to determine DA levels was performed as previously described (17). To determine DA released from differentiated precursor cells with or without terminal differentiation, ITSA media conditioned in the cells for 24 hours were collected. DA release evoked by depolarization was also determined in terminally differentiated cells. Cells at terminal differentiation day 15 were incubated in ITSA with (evoked) or without (basal release) 56 mmol/l KCl for 30 minutes, and the media were collected. The collected medium was stabilized with 0.1 N perchloric acid containing 0.1 mmol/l EDTA, followed by extraction by aluminum adsorption. DA was separated on a reverse-phase l-Bondapak C18 column (150 • 3.0 mm; Eicom) at a flow rate of 0.5 ml/min. Electroactive compounds were analyzed at +750 mV using an analytical cell and an amperometric detector (Model ECD-300; Eicom). DA levels were calculated using an internal standard (50 nmol/l methyl-DOPA) and catecholamine standard mixtures, including 1–50 nmol/l DA (external standard) injected immediately before and after each experiment.

In vivo transplantation and histological procedure.

The generation of 6-hydroxydopamine–lesioned PD model rats and the amphetamine-induced rotation test were performed as described previously (17). For transplantation, 3 different conditions for the preparation of Pro-1 NPCs were used (condition 1, NPC P1–P2, 2.5 × 105 cells /μl, 3 μl; condition 2, NPC P4, 1 × 105 cells/μl, 3 μl; condition 3, predifferentiated NPCs, 1 × 105 cells/μl, 3 μl). Dissociated Pro-1 NPCs were injected over a 5-minute period into each of 2 sites of the striatum (coordinates in AP, ML, and V relative to bregma and dura: [a] 0.07, –0.30, –0.55; [b] –0.10, –0.40, –0.50; incisor bar set at 3.5 mm below 0) under anesthesia induced by ketamine (4.5 mg/kg) mixed with Rompun (93.28 μg/kg). The needle (22 gauge) was left in place for 5 minutes after completion of each injection. Rats received daily injections of cyclosporine A (10 mg/kg i.p.) starting 1 day before grafting and continuing for 8 weeks thereafter. 8 weeks after transplantation, animals were anesthetized (50 mg/kg pentobarbital) and perfused intracardially with 4% paraformaldehyde. Brains were removed and immersed in 30% sucrose in PBS overnight, frozen in Tissue-Tek (Sakura Finetek USA), and then sliced on a freezing microtome (Leica). Free-floating brain sections (30 μm thick) were subjected to immunohistochemistry as described above, and images were obtained with a confocal microscope (Leica). The total number of cells positive for TH in the graft was counted. To compensate for double counting in adjacent sections, Abercrombie correction factor (N = n × T/[T + D]; where N is the actual number of cells, n is the number of nuclear profiles, T is the section thickness, and D is the average diameter of nuclei) was used. Graft areas were determined using LAS image analysis, and the Cavalieri estimator was used to calculate graft volumes.

Cell counting.

Immunoreactive cells on coverslip cultures were counted on randomly selected microscopic fields in a region of uniform cell growth using an eyepiece grid at a final magnification of ×200 or ×400. On each coverslip, 10–20 microscopic fields were counted, and 2–3 coverslips were analyzed in each experimental group.


Data are expressed as mean ± SEM of at least 3 independent experiments. Statistical comparisons were made by Student’s 2-tailed t test and 2-tailed paired t test, ANOVA, with Scheffe or Tukey post-hoc analysis (SPSS 15.0) when 2 or more groups were involved. The 2-tailed paired t test was applied for comparison of HPLC with or without KCl.

Supplementary Material

Supplemental data:


This work was supported by the Future-based Technology Development Program (grant 2010-0020232); the Medical Research Center (grant 2010-0029474); the Stem Cell Research Center of the 21st Century Frontier Research (grant SC4150), funded by the National Research Foundation (NRF) of the Ministry of Education, Science and Technology, Republic of Korea; and the NIH (grants MH087903 and NS070577).


Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2011;121(6):2326–2335. doi:10.1172/JCI45794.

Wonhee Suh’s present address is: College of Pharmacy, Ajou University, Seoul, Republic of Korea.


1. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006;116(7):1744–1754. doi: 10.1172/JCI29178. [PMC free article] [PubMed] [Cross Ref]
2. Piccini P, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient. Nat Neurosci. 1999;2(12):1137–1140. doi: 10.1038/16060. [PubMed] [Cross Ref]
3. Freed CR, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med. 2001;344(10):710–719. doi: 10.1056/NEJM200103083441002. [PubMed] [Cross Ref]
4. Dunnett SB, Bjorklund A, Lindvall O. Cell therapy in Parkinson’s disease - stop or go? Nat Rev Neurosci. 2001;2(5):365–369. doi: 10.1038/35072572. [PubMed] [Cross Ref]
5. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676. [PubMed]
6. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872. doi: 10.1016/j.cell.2007.11.019. [PubMed] [Cross Ref]
7. Yu J, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–1920. [PubMed]
8. Park IH, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451(7175):141–146. doi: 10.1038/nature06534. [PubMed] [Cross Ref]
9. Gearhart J, Pashos EE, Prasad MK. Pluripotency redux--advances in stem-cell research. N Engl J Med. 2007;357(15):1469–1472. doi: 10.1056/NEJMp078126. [PubMed] [Cross Ref]
10. Kim D, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4(6):472–476. doi: 10.1016/j.stem.2009.05.005. [PMC free article] [PubMed] [Cross Ref]
11. Osafune K, et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol. 2008;26(3):313–315. doi: 10.1038/nbt1383. [PubMed] [Cross Ref]
12. Miura K, et al. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol. 2009;27(8):743–745. [PubMed]
13. Hu BY, et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A. 2010;107(9):4335–4340. doi: 10.1073/pnas.0910012107. [PubMed] [Cross Ref]
14. Kawasaki H, et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron. 2000;28(1):31–40. doi: 10.1016/S0896-6273(00)00083-0. [PubMed] [Cross Ref]
15. Perrier AL, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci U S A. 2004;101(34):12543–12548. doi: 10.1073/pnas.0404700101. [PubMed] [Cross Ref]
16. Kim DW, et al. Stromal cell-derived inducing activity, Nurr1, and signaling molecules synergistically induce dopaminergic neurons from mouse embryonic stem cells. Stem Cells. 2006;24(3):557–567. doi: 10.1634/stemcells.2005-0233. [PMC free article] [PubMed] [Cross Ref]
17. Ko JY, et al. Human embryonic stem cell-derived neural precursors as a continuous, stable, and on-demand source for human dopamine neurons. . J Neurochem. 2007;103(4):1417–1429. doi: 10.1111/j.1471-4159.2007.04898.x. [PubMed] [Cross Ref]
18. Shen Q, et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science. 2004;304(5675):1338–1340. doi: 10.1126/science.1095505. [PubMed] [Cross Ref]
19. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med. 2006;12(11):1259–1268. doi: 10.1038/nm1495. [PubMed] [Cross Ref]
20. Pankratz MT, Li XJ, Lavaute TM, Lyons EA, Chen X, Zhang SC. Directed neural differentiation of human embryonic stem cells via an obligated primitive anterior stage. Stem Cells. 2007;25(6):1511–1520. doi: 10.1634/stemcells.2006-0707. [PMC free article] [PubMed] [Cross Ref]
21. Elkabetz Y, Panagiotakos G, Al Shamy G, Socci ND, Tabar V, Studer L. Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev. 2008;22(2):152–165. doi: 10.1101/gad.1616208. [PubMed] [Cross Ref]
22. LaVaute TM, Yoo YD, Pankratz MT, Weick JP, Gerstner JR, Zhang SC. Regulation of neural specification from human embryonic stem cells by BMP and FGF. Stem Cells. 2009;27(8):1741–1749. doi: 10.1002/stem.99. [PMC free article] [PubMed] [Cross Ref]
23. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008;322(5903):949–953. doi: 10.1126/science.1164270. [PubMed] [Cross Ref]
24. Graham V, Khudyakov J, Ellis P, Pevny L. SOX2 functions to maintain neural progenitor identity. Neuron. 2003;39(5):749–765. doi: 10.1016/S0896-6273(03)00497-5. [PubMed] [Cross Ref]
25. Kim JB, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature. 2008;454(7204):646–650. doi: 10.1038/nature07061. [PubMed] [Cross Ref]
26. Favaro R, et al. Hippocampal development and neural stem cell maintenance require Sox2-dependent regulation of Shh. Nat Neurosci. 2009;12(10):1248–1256. doi: 10.1038/nn.2397. [PubMed] [Cross Ref]
27. Chung S, et al. Neural precursors derived from embryonic stem cells, but not those from fetal ventral mesencephalon, maintain the potential to differentiate into dopaminergic neurons after expansion in vitro. Stem Cells. 2006;24(6):1583–1593. doi: 10.1634/stemcells.2005-0558. [PMC free article] [PubMed] [Cross Ref]
28. Hong S, Kang UJ, Isacson O, Kim KS. Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons. J Neurochem. 2008;104(2):316–324. [PMC free article] [PubMed]
29. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol. 2007;8(9):703–713. doi: 10.1038/nrm2241. [PubMed] [Cross Ref]
30. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009;458(7242):1127–1130. [PMC free article] [PubMed]
31. Lee SH, Ho WK. Characterization of somatic Ca2+ clearance mechanisms in young and mature hippocampal granule cells. Cell Calcium. 2009;45(5):465–473. [PubMed]
32. Hamaguchi I, et al. Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J Virol. 2000;74(22):10778–10784. doi: 10.1128/JVI.74.22.10778-10784.2000. [PMC free article] [PubMed] [Cross Ref]
33. Laker C, et al. Host cis-mediated extinction of a retrovirus permissive for expression in embryonal stem cells during differentiation. J Virol. 1998;72(1):339–348. [PMC free article] [PubMed]
34. Feng Q, et al. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells. 2010;28(4):704–712. doi: 10.1002/stem.321. [PubMed] [Cross Ref]
35. Kim JB, et al. Direct reprogramming of human neural stem cells by OCT4. Nature. 2009;461(7264):649–643. [PubMed]
36. Borowiak M, et al. Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell. 2009;4(4):348–358. [PubMed]
37. Lin T, et al. A chemical platform for improved induction of human iPSCs. Nat Methods. 2009;6(11):805–808. [PubMed]
38. Soldner F, et al. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009;136(5):964–977. doi: 10.1016/j.cell.2009.02.013. [PMC free article] [PubMed] [Cross Ref]
39. Woltjen K, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009;458(7239):766–770. doi: 10.1038/nature07863. [PubMed] [Cross Ref]
40. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature. 2009;458(7239):771–775. doi: 10.1038/nature07864. [PMC free article] [PubMed] [Cross Ref]
41. Yu J, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009;324(5928):797–801. doi: 10.1126/science.1172482. [PMC free article] [PubMed] [Cross Ref]
42. Jia F, et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods. 2010;7(3):197–199. doi: 10.1038/nmeth.1426. [PMC free article] [PubMed] [Cross Ref]
43. Hargus G, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A. 2010;107(36):15921–15926. doi: 10.1073/pnas.1010209107. [PubMed] [Cross Ref]
44. Swistowski A, et al. Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem Cells. 2010;28(10):1893–1904. doi: 10.1002/stem.499. [PMC free article] [PubMed] [Cross Ref]
45. Park CH, et al. In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. . J Neurochem. 2005;92(5):1265–1276. doi: 10.1111/j.1471-4159.2004.03006.x. [PubMed] [Cross Ref]
46. Jo AY, et al. Generation of dopamine neurons with improved cell survival and phenotype maintenance using a degradation-resistant nurr1 mutant. Stem Cells. 2009;27(9):2238–2246. doi: 10.1002/stem.146. [PMC free article] [PubMed] [Cross Ref]
47. Lee TH, et al. Functional recapitulation of smooth muscle cells via induced pluripotent stem cells from human aortic smooth muscle cells. Circ Res. 2010;106(1):120–128. doi: 10.1161/CIRCRESAHA.109.207902. [PubMed] [Cross Ref]
48. Carpenter MK, Rosler E, Rao M. Characterization and differentiation of human embryonic stem cells. Cloning Stem Cells. 2003;5(1):79–88. doi: 10.1089/153623003321512193. [PubMed] [Cross Ref]
49. Thomson JA, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145–1147. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation